Health LUND Women's Project (n = 6917) was launched in 1995 the cohort study with a postal questionnaire, physical examination, bone density measurement and blood laboratory analyzes. The fracture data were added, and this risk ratio fracture and its association with sex hormones was in postmenopausal women without current hormonal (HT) treatment analyzed. Postmenopausal women without total HT of 409 women (mean age 56.8 years) were identified with 489 fractures at a median follow-up of 8.4 years. (P = 0.005), testosterone / SHBG ratio (p = 0.003), and higher SHBG values (P = 0.005), were women with hemodialysis Of fractures compared with no fractures. There was no difference in estradiol levels.
Androstenedione and the ratio androstenedione / SHBG were divided into percentiles. An increased risk of fracture in postmenopausal women with androstenedione in the 5th percentile at 11-89. Percentile HR 1.51 (95% CI 1.02-2.24) found. The ratio of androstenedione / SHBG (11-89 Percentile for reference) showed an increased risk of fracture in women with a low ratio of the 5th percentile HR 1.75 (95% CI 1.20 to 2.54) and Reduces the risk of fracture with a high ratio 95th percentile HR 0.52 (95% CI 0.28 -0.98). An increased risk of fracture during follow-up was observed in postmenopausal women with a low serum androstenedion- and androstenedione / SHBG level at baseline and a lower risk of high ratio fracture / androstenedione SHBG. This study suggests that postmenopausal osteoporosis is influenced by lower androgen levels.
